CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤 CAR-T 治疗的挑战与最优策略
英文原题：Challenges and optimal strategies of CAR T therapy for hematological malignancies.
查看英文原题
Challenges and optimal strategies of CAR T therapy for hematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法治疗血液系统恶性肿瘤的效果显著优于传统方法，过去 5 年内已有 8 种商业 CAR-T 产品相继获批。尽管 CAR-T 产品化正迅速推动其在真实世界患者中的广泛临床应用，但疗效受限及相关毒性促使研究者进一步优化 CAR 结构，并在多种治疗情境下开展大量创新试验。本文首先总结 CAR-T 疗法治疗血液系统恶性肿瘤的现状和主要进展，随后介绍可能损害 CAR-T 细胞临床疗效的关键因素，如 CAR-T 细胞耗竭和抗原丢失，最后讨论应对该领域挑战的潜在优化策略。
展开英文摘要原文
Remarkable improvement relative to traditional approaches in the treatment of hematological malignancies by chimeric antigen receptor (CAR) T-cell therapy has promoted sequential approvals of eight commercial CAR T products within last 5 years. Although CAR T cells' productization is now rapidly boosting their extensive clinical application in real-world patients, the limitation of their clinical efficacy and related toxicities inspire further optimization of CAR structure and substantial development of innovative trials in various scenarios.
Herein, we first summarized the current status and major progress in CAR T therapy for hematological malignancies, then described crucial factors which possibly compromise the clinical efficacies of CAR T cells, such as CAR T cell exhaustion and loss of antigen, and finally, we discussed the potential optimization strategies to tackle the challenges in the field of CAR T therapy.
论文信息
- 作者
- Zhang Y、Xu Y、Dang X、Zhu Z、Qian W、Liang A、Han W
- 单位
- Department of Bio-Therapeutics, The First Medical Centre, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.China
- 期刊
- Chinese medical journal2023 Feb 5
- 原文标识
- PubMed 36848181 · DOI 10.1097/CM9.0000000000002476
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →